权利要求:
1. A condom comprising an internal skin-contacting surface and an external skin-contacting surface, wherein at least one of the internal skin-contacting surface and the external skin-contacting surface is lubricated with an antiviral lubricous composition, wherein the antiviral lubricous composition consists of:(a) from about 0.1% to about 5% by weight of carrageenan;(b) from about 0.1% to about 50% by weight of one or more polyols; and(c) from about 0.01% to about 1% by weight of one or more pH-adjusting agents;(d) water; and(e) optionally, one or more selected from the group consisting of a sweetener, a preservative, a zinc salt, and a spermicide; andwherein:(i) from about 80% to about 95% by weight of the carrageenan is lambda-carrageenan;(ii) from about 5% to about 20% by weight of the carrageenan is one or both of kappa-carrageenan and iota-carrageenan;(iii) the one or more polyols are selected from the group consisting of glycerol, propylene glycol, 1,3-propanediol, 1,3-butanediol, 1,4-butanediol, 2,3-butanediol, xylitol sorbitol, erythritol, isomalt, lactitol, maltitol, mannitol, polyethylene glycol, polypropylene glycol;(iv) the one or more pH-adjusting agents comprise at least one organic acid and its conjugate base;(v) the antiviral lubricious composition has a viscosity of from about 500 cP to about 10,000 cP;(vi) the antiviral lubricious composition has an osmolality of from about 250 mOsmol/kg up to less than 1,200 mOsmol/kg;(vii) the antiviral lubricious composition is an aqueous homogeneous solution having a turbidity less than or equal to about 25 Nephelometric Turbidity Units (NTU); and(viii) the pH of the antiviral lubricious composition is from about 3.5 to about 8.0.2. The condom according to claim 1, wherein at least about 90% by weight of the carrageenan is lambda-carrageenan.3. The condom according to claim 1, wherein the antiviral lubricous composition contains at least about 1.5% by weight, and up to about 1.7% by weight, of the sea carrageenan.4. The condom according to claim 1, wherein the antiviral lubricous composition contains saccharin as the sweetener, and wherein the amount of saccharin present in the antiviral lubricious composition is less than 5% by weight.5. The condom according to claim 1, wherein the antiviral lubricous composition contains the preservative, and wherein the amount of the preservative present in the antiviral composition is less than about 1% by weight.6. The condom according to claim 1, wherein the one or more polyols is solely propylene glycol.7. The condom according to claim 1, wherein the condom is contained within a watertight packaging that seals the condom from an external environment outside of the packaging.8. The condom according to claim 1, wherein the antiviral lubricious composition contains the zinc salt.9. The condom according to claim 5, wherein the preservative is selected from the group consisting of methylparaben, benzoic acid, salicylic acid, sorbic acid, polyparaben, sodium dehydroacetate and combinations thereof.10. The condom according to claim 1, wherein the condom is made of latex.11. The condom according to claim 1, wherein the antiviral lubricious composition contains the spermicide.12. The condom according toclaim 1, wherein the antiviral lubricious composition has a viscosity of from about 1,500 cP to about 2,500 cP.13. The condom according to claim 1, wherein the antiviral lubricious composition has a turbidity less than or equal to about 5 Nephelometric Turbidity Units (NTU).14. The condom according to claim 1, wherein the antiviral lubricious composition is transparent, and there are substantially zero particulates, aggregates or agglomerates visible within the antiviral lubricious composition.15. The condom according to claim 1, wherein the at least one organic acid is citric acid and its conjugate base is sodium citrate and/or magnesium citrate.16. The condom according to claim 1, wherein about 0.5% to about 2.3% by weight of the antiviral lubricious composition is carrageenan, wherein the antiviral lubricious composition has a viscosity of less than about 5,000 cP, wherein the antiviral lubricious composition is translucent, and wherein the antiviral lubricious composition has a turbidity of less than about 5 Nephelometric Turbidity Units (NTU).